CelLBxHealth plc, a specialist in circulating tumour cell (CTC) intelligence for research, drug development and clinical oncology, has announced a series of board appointments.

Peter Collins has been appointed CEO, alongside new non-executive directors Klaas de Boer, Kim Oreskovic and Benjamin Hart.

Separately, non-executive director Joseph Eid will step down from the board at the end of the month.

The changes follow the company’s December update and are intended to strengthen leadership as it advances its Parsortix CTC platform across oncology research and clinical applications.